Download MendeleyBRD-810 is a highly selective MCL1 inhibitor with optimized in vivo clearance and robust efficacy in solid and hematological tumor models.
Rauh, U., Wei, G., Serrano-Wu, M., Kosmidis, G., Kaulfuss, S., Siegel, F., Thede, K., McFarland, J., Lemke, C.T., Werbeck, N., Nowak-Reppel, K., Pilari, S., Menz, S., Ocker, M., Zhang, W., Davis, K., Poncet-Montange, G., Roth, J., Daniels, D., Kaushik, V.K., Hubbard, B., Ziegelbauer, K., Golub, T.R.(2024) Nat Cancer 5: 1479-1493
- PubMed: 39179926
- DOI: https://doi.org/10.1038/s43018-024-00814-0
- Primary Citation of Related Structures:
8T6F - PubMed Abstract:
The MCL1 gene is frequently amplified in cancer and codes for the antiapoptotic protein myeloid cell leukemia 1 (MCL1), which confers resistance to the current standard of care. Therefore, MCL1 is an attractive anticancer target. Here we describe BRD-810 as a potent and selective MCL1 inhibitor and its key design principle of rapid systemic clearance to potentially minimize area under the curve-driven toxicities associated with MCL1 inhibition. BRD-810 induced rapid cell killing within 4 h in vitro but, in the same 4-h window, had no impact on cell viability or troponin I release in human induced pluripotent stem cell-derived cardiomyocytes, even at suprapharmacologic concentrations. In vivo BRD-810 induced efficacy in xenograft hematological and solid tumor models despite the short residence time of BRD-810 in plasma. In totality, our data support the hypothesis that short-term inhibition of MCL1 with BRD-810 can induce apoptosis in tumor cells while maintaining an acceptable safety profile. We, therefore, intend to advance BRD-810 to clinical trials.
Organizational Affiliation:
Trueline Therapeutics Inc., Cambridge, MA, USA. ulla@truelinetx.com.
